Business Parks & Science Centres

 
 
 

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 600x94px
Collaboration › Details

Regeneron–ERS Genomics: CRISPR technology, 201511– license €na for use in drug discovery + development

 

Period Period 2015-11-24
Organisations Partner, 1st Regeneron Pharmaceuticals Inc. (Nasdaq: REGN)
  Partner, 2nd ERS Genomics Ltd.
Products Product CRISPR gene editing technology
  Product 2 drug discovery
     

ERS Genomics Ltd.. (11/24/15). "Press Release: ERS Genomics Licenses Genome-editing Patents to Regeneron Pharmaceuticals". Dublin.

ERS Genomics (ERS) today announced a patent license agreement whereby Regeneron Pharmaceuticals gains access to ERS’ CRISPR-Cas9 genome-editing patents for use in drug discovery and development. ERS Genomics holds rights to foundational CRISPR-Cas9 patent portfolio from Dr. Emmanuelle Charpentier, an inventor of the breakthrough gene-editing technology.

"We are pleased to include Regeneron, a leading biopharmaceutical company, into our portfolio of licensees,” said Shaun Foy, CEO and Founder of ERS Genomics. “Genome editing has many applications in drug discovery and development and making the CRISPR-Cas9 patents widely available to biotechnology and pharmaceutical companies is an important part of ERS Genomics’ strategy."

Dr. Emmanuelle Charpentier’s research unveiled the key components and mechanisms of the CRISPR-Cas9 system, leading to the landmark publication with Jennifer Doudna, (Jinek et al., 2012), which laid the foundation for the use of CRISPR-Cas9 as a highly versatile and precise genome-editing tool.

Financial details of the agreement were not disclosed.


ERS Genomics was formed to provide broad access to the foundational CRISPR-Cas9 intellectual property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses are available for research and sale of products and services across multiple fields including: research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology. For additional information please visit www.ersgenomics.com.


Contact:

Douglas MacDougall
MacDougall Biomedical Communications
dmacdougall@macbiocom.com
781.235.3060

   
Record changed: 2019-04-13

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Regeneron Pharmaceuticals Inc. (Nasdaq: REGN)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 600x94px




» top